Device Embolization in Structural Heart InterventionsIncidence, Outcomes, and Retrieval Techniques
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click the login link or the subscribe link in the top menu above to access this article.
Author + information
- Mohamad Alkhouli, MDa,∗ (Mohamad.Alkhouli{at}wvumedicine.org),
- Horst Sievert, MDb and
- Charanjit S. Rihal, MDc
- aDivision of Cardiology, West Virginia University, Morgantown, West Virginia
- bCardiovascular Center Frankfurt, Frankfurt, Germany; Anglia Ruskin University, Chelmsford, United Kingdom
- cDepartment of Cardiology, Mayo Clinic School of Medicine, Rochester, Minnesota
- ↵∗Address for correspondence:
Dr. Mohamad Alkhouli, West Virginia University Heart & Vascular Institute, 1 Medical Drive, Morgantown, West Virginia 26505.
Central Illustration
Abstract
Device embolization is a rare complication of transcatheter structural heart interventions. Although the majority of device embolizations can be treated in a semielective manner, some are life threatening and require prompt intervention. Awareness of this potential complication, and knowledge of retrieval tools and techniques are essential to the structural interventionalist. This paper offers a succinct review of the incidence, and outcomes of device embolization during common structural heart interventions. It also provides an overview of the essential component of the “percutaneous retrieval toolbox” and suggests a systematic algorithmic approach for the management of device embolization.
Footnotes
Dr. Sievert has received study honoraria, travel expenses, and consulting fees from 4Tech Cardio, Abbott, Ablative Solutions, Ancora Heart, Bavaria Medizin Technologie, Bioventrix, Boston Scientific, Carag, Cardiac Dimensions, Celonova, Cibiem, CGuard, Comed B.V., Contego, CVRx, Edwards Lifesciences, Endologix, Hemoteq, InspireMD, Lifetech, Maquet Getinge Group, Medtronic, Mitralign, Nuomao Medtech, Occlutech, pfm Medical, Recor, Renal Guard, Rox Medical, Terumo, Vascular Dynamics, and Vivasure Medical.
- Received May 21, 2018.
- Revision received July 16, 2018.
- Accepted August 21, 2018.
- 2019 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.
